Kiniksa Pharmaceuticals International (KNSA) Total Current Liabilities (2017 - 2026)

Kiniksa Pharmaceuticals International (KNSA) has 10 years of Total Current Liabilities data on file, last reported at $171.2 million in Q2 2026.

• Quarterly Total Current Liabilities rose 45.34% year-over-year to $171.2 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $171.2 million (up 45.34% YoY) and the FY2025 annual result came in at $139.2 million, up 38.33% from the prior year.
• Total Current Liabilities improved to $171.2 million in Q2 2026, from $156.6 million in the prior quarter.
• In the past five years, Total Current Liabilities ranged from a high of $171.2 million in Q2 2026 to a low of $36.6 million in Q1 2023.
• A 5-year average of $86.1 million and a median of $74.3 million in 2024 frame the typical range for Total Current Liabilities.
• Annual changes were most pronounced in 2023 — Total Current Liabilities decreased 27.34% — and 2024, when it surged 79.46%.
• Tracing KNSA's Total Current Liabilities over 5 years: stood at $47.1 million in 2022, then soared by 35.27% to $63.7 million in 2023, then surged by 58.05% to $100.6 million in 2024, then surged by 38.33% to $139.2 million in 2025, then advanced by 23.04% to $171.2 million in 2026.
• The last three Total Current Liabilities figures came in at $171.2 million (Q2 2026), $156.6 million (Q1 2026), and $139.2 million (Q4 2025), per Business Quant data.